Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

John Barrett

Showing results (291-300 of 349) with videos related to

Pageof 35
Sort By:
Blood|May 10, 2005
Prospective evaluation of 2 acute graft-versus-host (GVHD) grading systems: a joint Société Française de Greffe de Moëlle et Thérapie Cellulaire (SFGM-TC), Dana Farber Cancer Institute (DFCI), and International Bone Marrow Transplant Registry (IBMTR) prospective studyJean-Yves Cahn, John P Klein, Stephanie J Lee, et al.
Bioconjugate Chemistry|June 21, 2007
Radiolabeled divalent peptidomimetic vitronectin receptor antagonists as potential tumor radiotherapeutic and imaging agentsThomas D Harris, Edward Cheesman, Anthony R Harris, et al.
The Journal of Biological Chemistry|August 13, 2013
Discovery of novel irreversible inhibitors of interleukin (IL)-2-inducible tyrosine kinase (Itk) by targeting cysteine 442 in the ATP pocketJohn D Harling, Angela M Deakin, Sébastien Campos, et al.
Haematologica|February 4, 2014
Leukemia-induced phenotypic and functional defects in natural killer cells predict failure to achieve remission in acute myeloid leukemiaKate Stringaris, Takuya Sekine, Ahmad Khoder, et al.
Cytotherapy|April 9, 2021
Identification of novel HLA-restricted preferentially expressed antigen in melanoma peptides to facilitate off-the-shelf tumor-associated antigen-specific T-cell therapiesMaja Stanojevic, Amy B Hont, Ashley Geiger, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 12, 2002
Prospective trial of chemotherapy and donor leukocyte infusions for relapse of advanced myeloid malignancies after allogeneic stem-cell transplantationJohn E Levine, Thomas Braun, Samuel L Penza, et al.
Journal of Medicinal Chemistry|October 17, 2024
Core Modifications of GSK3335103 toward Orally Bioavailable α<sub>v</sub>β<sub>6</sub> Inhibitors with Improved Synthetic TractabilityHeather F Hryczanek, John Barrett, Tim N Barrett, et al.
Experimental Hematology|January 30, 2007
Changes in salivary proteome following allogeneic hematopoietic stem cell transplantationMatin M Imanguli, Jane C Atkinson, Kristen E Harvey, et al.
Journal of Immunology (Baltimore, Md. : 1950)|August 9, 2011
Allogeneic HLA-A*02-restricted WT1-specific T cells from mismatched donors are highly reactive but show off-target promiscuityWillem J J Falkenburg, J Joseph Melenhorst, Marian van de Meent, et al.
Blood Advances|September 11, 2019
Persistence of skewed X-chromosome inactivation in pre-B acute lymphoblastic leukemia of a female ATRX mutation carrierChristian P Bradley, Cai Chen, Karolyn A Oetjen, et al.
Pageof 35

Showing results (291-300 of 349) with videos related to

Sort By:
Pageof 35
Blood|May 10, 2005
Prospective evaluation of 2 acute graft-versus-host (GVHD) grading systems: a joint Société Française de Greffe de Moëlle et Thérapie Cellulaire (SFGM-TC), Dana Farber Cancer Institute (DFCI), and International Bone Marrow Transplant Registry (IBMTR) prospective studyJean-Yves Cahn, John P Klein, Stephanie J Lee, et al.
Bioconjugate Chemistry|June 21, 2007
Radiolabeled divalent peptidomimetic vitronectin receptor antagonists as potential tumor radiotherapeutic and imaging agentsThomas D Harris, Edward Cheesman, Anthony R Harris, et al.
The Journal of Biological Chemistry|August 13, 2013
Discovery of novel irreversible inhibitors of interleukin (IL)-2-inducible tyrosine kinase (Itk) by targeting cysteine 442 in the ATP pocketJohn D Harling, Angela M Deakin, Sébastien Campos, et al.
Haematologica|February 4, 2014
Leukemia-induced phenotypic and functional defects in natural killer cells predict failure to achieve remission in acute myeloid leukemiaKate Stringaris, Takuya Sekine, Ahmad Khoder, et al.
Cytotherapy|April 9, 2021
Identification of novel HLA-restricted preferentially expressed antigen in melanoma peptides to facilitate off-the-shelf tumor-associated antigen-specific T-cell therapiesMaja Stanojevic, Amy B Hont, Ashley Geiger, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 12, 2002
Prospective trial of chemotherapy and donor leukocyte infusions for relapse of advanced myeloid malignancies after allogeneic stem-cell transplantationJohn E Levine, Thomas Braun, Samuel L Penza, et al.
Journal of Medicinal Chemistry|October 17, 2024
Core Modifications of GSK3335103 toward Orally Bioavailable α<sub>v</sub>β<sub>6</sub> Inhibitors with Improved Synthetic TractabilityHeather F Hryczanek, John Barrett, Tim N Barrett, et al.
Experimental Hematology|January 30, 2007
Changes in salivary proteome following allogeneic hematopoietic stem cell transplantationMatin M Imanguli, Jane C Atkinson, Kristen E Harvey, et al.
Journal of Immunology (Baltimore, Md. : 1950)|August 9, 2011
Allogeneic HLA-A*02-restricted WT1-specific T cells from mismatched donors are highly reactive but show off-target promiscuityWillem J J Falkenburg, J Joseph Melenhorst, Marian van de Meent, et al.
Blood Advances|September 11, 2019
Persistence of skewed X-chromosome inactivation in pre-B acute lymphoblastic leukemia of a female ATRX mutation carrierChristian P Bradley, Cai Chen, Karolyn A Oetjen, et al.
Pageof 35